Evidence map›Paper›PMID 32896909›Full record

ArticleThe EMBO journal2020

HIV-1 capsids mimic a microtubule regulator to coordinate early stages of infection.

Eveline Santos da Silva, Shanmugapriya Shanmugapriya, Viacheslav Malikov, Feng Gu, M Keegan Delaney, Mojgan H Naghavi

Open access · greenAbstract read
In one paragraph

Article in The EMBO journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Virus infection and vesicle trafficking.Frontiers in immunology · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Capsid-host interactions for HIV-1 ingress.Microbiology and molecular biology reviews : MMBR · 2023
    Review
  8. Review
  9. Article
  10. Trim69 is a microtubule regulator that acts as a pantropic viral inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Dynactin 1 negatively regulates HIV-1 infection by sequestering the host cofactor CLIP170.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eveline Santos da SilvaDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Shanmugapriya ShanmugapriyaDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Viacheslav MalikovDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Feng GuDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
M Keegan DelaneyDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Mojgan H NaghaviDepartment of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0001-8645-5839
Northwestern University · US

Funding

The Role of the Microtubule Regulators Kif4 and EB1 in HIV-1 InfectionP01GM105536 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GOFF, STEPHEN PAINE, GUNDERSEN, GREGG G · 2014 to 2018
$7.5M
TRAINING PROGRAM IN IMMUNOLOGY &MOLECULAR PATHOGENESIST32AI007476 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Edward Benjamin Thorp · 1996 to 2026
$6.6M
The role of FEZ1 in early HIV-1 infectionR01AI150559 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NAGHAVI, MOJGAN HOSSEINI · 2019 to 2023
$1.8M
Characterization of the antiviral and nuclear regulatory functions of FEZ1 & NEK1R01GM101975 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NAGHAVI, MOJGAN HOSSEINI · 2012 to 2016
$1.6M
NIAID NIH HHS R01 AI150559NIAID NIH HHS T32 AI007476NIGMS NIH HHS P01 GM105536NIGMS NIH HHS R01 GM101975
6 · The paper itself

Abstract

While the microtubule end-binding protein, EB1 facilitates early stages of HIV-1 infection, how it does so remains unclear. Here, we show that beyond its effects on microtubule acetylation, EB1 also indirectly contributes to infection by delivering the plus-end tracking protein (+TIP), cytoplasmic linker protein 170 (CLIP170) to the cell periphery. CLIP170 bound to intact HIV-1 cores or in vitro assembled capsid-nucleocapsid complexes, while EB1 did not. Moreover, unlike EB1 and several other +TIPs, CLIP170 enhanced infection independently of effects on microtubule acetylation. Capsid mutants and imaging revealed that CLIP170 bound HIV-1 cores in a manner distinct from currently known capsid cofactors, influenced by pentamer composition or curvature. Structural analyses revealed an EB-like +TIP-binding motif within the capsid major homology region (MHR) that binds SxIP motifs found in several +TIPs, and variability across this MHR sequence correlated with the extent to which different retroviruses engage CLIP170 to facilitate infection. Our findings provide mechanistic insights into the complex roles of +TIPs in mediating early stages of retroviral infection, and reveal divergent capsid-based EB1 mimicry across retroviral species.

Indexed as

Host Microbial InteractionsAmino Acid MotifsAnimalsCapsidCell LineHIV-1HIV InfectionsHumansMacacaMicrotubule-Associated ProteinsMicrotubulesMolecular MimicryNeoplasm ProteinsProtein BindingRNA, Small Interferingcytoplasmic linker protein 170MAPRE1 protein, humanMicrotubule-Associated ProteinsNeoplasm ProteinsRNA, Small InterferingCLIP170HIV-1+TIPtraffickinguncoating

Identifiers

PMID32896909
PMCPMC7560205
OpenAlexW3084070727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.